Overview

A Phase 2, Open Label, Single Arm, Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma

Status:
Not yet recruiting

Trial end date:
2034-08-01

Target enrollment:

Participant gender:

Summary

Neoadjuvant therapy is feasible in stage II melanoma, and the dual inhibition of the distinct LAG-3 and PD-1 checkpoint pathways with relatlimab and nivolumab has a synergistic effect in the tumour microenvironment leading to a pathological response after 2 doses of therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Melanoma Institute Australia

Collaborator:

Bristol-Myers Squibb

Treatments:

Nivolumab